MediWound annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
MediWound Stock-Based Compensation Growth & History (MDWD)
MediWound's stock-based compensation was $3.1M for fiscal 2025.
View full MediWound company overviewMediWound annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.1M | −$30,000 | −0.96% |
| 2024 | 2024-12-31 | $3.1M | $1.2M | +61.75% |
| 2023 | 2023-12-31 | $1.9M | −$6,000 | −0.31% |
| 2022 | 2022-12-31 | $1.9M | $273,000 | +16.32% |
| 2021 | 2021-12-31 | $1.7M | $351,000 | +26.55% |
| 2020 | 2020-12-31 | $1.3M | $88,000 | +7.13% |
| 2019 | 2019-12-31 | $1.2M | $589,000 | +91.32% |
| 2018 | 2018-12-31 | $645,000 | −$718,000 | −52.68% |
| 2017 | 2017-12-31 | $1.4M | −$1.8M | −57.02% |
| 2016 | 2016-12-31 | $3.2M | $512,000 | +19.26% |
| 2015 | 2015-12-31 | $2.7M | — | — |
MediWound quarterly stock-based compensation
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $755,000 | −$107,000 | −12.41% |
| Q1 2026 | 2026-03-31 | $644,000 | −$200,000 | −23.70% |
| Q4 2025 | 2025-12-31 | $662,000 | — | — |
| Q3 2025 | 2025-09-30 | $740,000 | — | — |
| Q2 2025 | 2025-06-30 | $862,000 | $104,000 | +13.72% |
| Q1 2025 | 2025-03-31 | $844,000 | — | — |
| Q2 2024 | 2024-06-30 | $758,000 | $46,000 | +6.46% |
| Q2 2023 | 2023-06-30 | $712,000 | $460,000 | +182.54% |
| Q2 2022 | 2022-06-30 | $252,000 | −$248,000 | −49.60% |
| Q2 2021 | 2021-06-30 | $500,000 | $154,000 | +44.51% |
| Q2 2020 | 2020-06-30 | $346,000 | $22,000 | +6.79% |
| Q2 2019 | 2019-06-30 | $324,000 | $175,000 | +117.45% |
| Q2 2018 | 2018-06-30 | $149,000 | −$188,000 | −55.79% |
| Q2 2017 | 2017-06-30 | $337,000 | — | — |
MediWound stock-based compensation trends
Over the last five fiscal years, MediWound's stock-based compensation increased from $1.3M to $3.1M, a change of $1.8M. The latest reported quarter, Q2 2026, shows $755,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MediWound source filings ↗